Skip to Content

Markets
Technicals
Companies
Earnings
Close-Up
Themes

News

Market and company headlines

CLNNAll

Loading

A personal project for following the US markets. Free, ad-free and open source.

Weekly Recap

Every Sunday morning: the week's earnings behind you and the calendar ahead, in one email.

Get It by Email

Market

Markets
Companies
Stock Screener
Macro
Earnings
Technical Analysis
Calendar
Compare
Thematic Lists
Famous Investors

Reading

Guide
Close-Up
Community
News
Brief Archive
Glossary
Tax Calculator
RSS

Account

Watchlist
My Posts
Bell Report
Portfolio
Settings
Privacy

© 2026 Opening BellPrivacy About What's New ContactNot Investment AdviceAhmet Akyapı

Markets Earnings Close-Up Menu

Nasdaq 100 · QQQ721.22+ 1.27%S&P 500 · SPY769.93+ 0.60%Dow Jones · DIA523.42+ 0.09%Russell 2000 · IWM280.07+ 1.11%

12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers SCWorx (NASDAQ:WORX) stock moved upwards by 42.9% to $3.83 during Tuesday's regular session. Myriad Genetics (NASDAQ:MYGN) shares moved upwards by 36.85% to $5.76. The company's market cap stands at
Benzinga09:057 Days Ago

00:00Oct 201 Story

Why 3M Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
3M shares rose 4.4% premarket after expanding its Amazon data-center deal, including a $521.4M stock warrant; other stocks saw sharp moves.
Benzinga00:43

06:00-09:00Oct 192 Stories

Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS
NDA submission seeks accelerated approval of CNM-Au8 based on neurofilament light chain biomarker data and clinical outcomes SALT LAKE CITY, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on revolutionizing the treatment of neurodegenerative diseases, announced that it has submitted a New Drug Application (NDA) earlier in October to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of CNM-Au8® for the treatment o
Yahoo08:00CLNN
HC Wainwright & Co. Reiterates Buy on Clene, Maintains $31 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $31 price target.
Benzinga06:58CLNN

04:00Oct 191 Story

Clene Submits New Drug Application To FDA For Accelerated Approvla Of CNM-Au8
NDA submission seeks accelerated approval of CNM-Au8 based on neurofilament light chain biomarker data and clinical outcomes
Benzinga04:03CLNN

08:00Oct 21 Story

Clene Targets Q4 FDA Filing for ALS Drug CNM-Au8, Eyes Mid-2027 Decision
Clene (NASDAQ:CLNN) said it plans to submit a new drug application to the U.S. Food and Drug Administration at the beginning of the fourth quarter for CNM-Au8, its investigational treatment for amyotrophic lateral sclerosis, or ALS. In a fireside chat at the Lytham Partners Fall 2026 Investor Confe
Yahoo08:02CLNN

08:00Sep 221 Story

Clene to Present at Upcoming Investor Conferences
SALT LAKE CITY, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will participate at the 5th Annual ROTH Healthcare Opportunities Conference and at the Lytham Partners Investor Conference Fall Event and host 1x1 investor meetings at both conferences. 5th Annual ROTH Healthcare Opportunities ConferenceDate: September 29, 2026Location: New York, NYFormat: 1x1 meetings1x1 Meetings: Please contact your ROTH representative Lytham Partners Investor Conferenc
Yahoo08:00CLNN

08:00Sep 211 Story

Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA
Investment was led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene’s Chief Executive Officer and other existing shareholders$4 million registered direct offering was priced at market under Nasdaq rulesProceeds are expected to be sufficient to fund the Company to mid-first quarter 2027, which is beyond the potential FDA decision to accept the CNM-Au8® NDA for review under the accelerated approval pathway SALT LAKE CITY, Sept. 21, 2026
Yahoo08:30CLNN

05:00-10:00Sep 152 Stories

Clene Announces $4 Million Registered Direct Offering
Investment led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene’s Chief Executive Officer and other existing shareholders$4 million registered direct offering priced at market under Nasdaq rulesProceeds are expected to be sufficient to fund the Company to mid-first quarter 2027 SALT LAKE CITY, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on ALS, today announced the pricing
Yahoo09:00CLNN
Clene Prices Registered Direct Offering Of 1,219,513 Shares At $3.28/Shr To Existing Shareholders With Total Gross Proceeds Of $4M
Investment led by Clene’s Chairman of the Board of Directors, alongside founding investor Kensington Capital Holdings, Clene’s Chief Executive Officer and other existing shareholders$4 million registered direct offering
Benzinga05:01CLNN